Impact of single-dose nilotinib on the pharmacokinetic and pharmacodynamic profiles of single-dose warfarin in fed volunteers

Trial Profile

Impact of single-dose nilotinib on the pharmacokinetic and pharmacodynamic profiles of single-dose warfarin in fed volunteers

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2011

At a glance

  • Drugs Nilotinib; Warfarin
  • Indications Cancer; Thrombosis
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Novartis; Parexel International
  • Most Recent Events

    • 03 May 2011 New trial record
    • 01 Mar 2011 Results published in Clinical Drug Investigation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top